Daré Bioscience ((DARE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daré Bioscience, in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is conducting a study titled ‘An Open-Label, Four-Treatment, Parallel Study of the Comparative Pharmacokinetics of a Progesterone Intravaginal Ring (IVR) 8 mg and 12 mg/Day Versus Progesterone Vaginal Insert 100mg.’ The study aims to compare how different progesterone delivery methods affect hormone levels in the body, focusing on potential treatments for preterm birth.
The study tests various progesterone delivery methods, including an intravaginal ring (IVR) delivering 8 mg and 12 mg of progesterone daily, and a 100 mg progesterone vaginal insert. These interventions are designed to determine the most effective method for maintaining optimal progesterone levels to prevent preterm birth.
This interventional study employs a non-randomized, parallel assignment model without masking, focusing primarily on treatment purposes. Participants will receive different progesterone doses over 14 to 15 days to assess pharmacokinetic outcomes.
Key dates for the study include an anticipated start date of October 29, 2024, with the primary completion and estimated study completion dates yet to be announced. The latest update was submitted on September 2, 2025, indicating ongoing preparations for recruitment.
The study’s progress could influence Daré Bioscience’s stock performance by showcasing its commitment to innovative women’s health solutions. As the study is still in its early phases, investor sentiment may remain cautiously optimistic, especially considering the competitive landscape in women’s health therapeutics.
The study is ongoing, with further details available on the ClinicalTrials portal.